Article

Do “red flags” signal serious pathology with low back pain?

When patients present to primary care physicians with acute low back pain (LBP), a serious causative underlying pathology-cancer, fracture, or infection-is seldom identified. Some recommended “red flag” screening questions have high false-positive rates, casting doubt on the value of looking for bigger trouble when none is obvious.

When patients present to primary care physicians with acute low back pain (LBP), a serious causative underlying pathology-cancer, fracture, or infection-is seldom identified. Some recommended “red flag” screening questions have high false-positive rates, casting doubt on the value of looking for bigger trouble when none is obvious.

Henschke and colleagues evaluated the prevalence of serious pathology and the value of asking red flag screening questions in 1172 patients with LBP being seen by their primary care physician. Participating doctors recorded the responses to 25 questions and then provided an initial diagnosis.

Only 11 patients (0.9%) had serious pathology; 8 of the cases involved fracture. Only 3 of the screening questions provided useful information: prolonged use of corticosteroids, age older than 70 years, and significant trauma. Positive answers to these questions, along with female sex, were moderately associated with incidence of fracture. Most of the screening questions had a high rate of false-positive results, causing the investigators to avoid recommending their use as a worthwhile screening tool in persons with LBP.

The authors noted that the diagnostic accuracy of red flags for all serious pathology is an important but challenging topic for future research.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.